11/5/2026

speaker
Operator
Conference Call Operator

Greetings and welcome to ImmuneBio's 2026 Third Quarter Earnings Call. As a reminder, this conference is being recorded. A transcript will follow within 24 hours of this conference call. In this meeting, there will be no question and answer session. Should you have any inquiries, please email them to Mr. Dan Carson. It is my pleasure to introduce Mr. Dan Carson, Head of Investor Relations of ImmuneBio. Dan?

speaker
Dan Carson
Head of Investor Relations

Thank you, Operator, and good afternoon, everyone. We thank you for joining us for the call for ImmuneBio's third quarter 2026 financial results. Presenting on today's call are David Moss, CEO and co-founder of ImmuneBio, Dr. Mark Lowdell, Chief Scientific Officer and co-founder of ImmuneBio, and Cory Ellspermann, ImmuneBio CFO. Before we begin, I remind everyone that except for statements of historical fact, The statements made by management and responses to questions on this conference call are forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that can cause actual results to differ materially from those expressed or implied by such forward-looking statements. Please see the forward-looking statements disclaimer in the company's earnings press release, as well as risk factors in the company's SEC filings, including our most recent quarterly filings with the SEC. There is no assurance of any specific outcome. Undue reliance should not be placed on forward-looking statements which speak only as of the date they are made, as the facts and circumstances underlying these forward-looking statements may change. Except as required by law, Immune Bio disclaims any obligation to update these forward-looking statements to reflect future information, events, or circumstances. Now, my pleasure to turn the call over to Immune Bio CEO, David Moss.

speaker
David Moss
CEO and Co-Founder

Thank you, Dan, and good afternoon, everyone. Thank you for joining us for Immune Bio's third quarter 26 earnings call. This is an exciting time for Immune Bio. We're getting close to important milestones of entering a new phase in the company's development as we move Ebstracell towards regulatory approval and prepare to make it available to patients. During the quarter, we made important progress in manufacturing, regulatory preparation, and international patient expansion. Each of these steps brings us closer to our goal of transforming a new bio from a clinical stage company into a commercial stage company. The immediate focus is on execution as we're getting very close. This involves assembling the complete regulatory package, establishing a practical route to patient access, and carefully allocating capital to these milestones. I want to be clear about our confidence in these activities. We believe the clinical data presents a compelling case for Ebstracell as a potentially first-in-class systemic treatment in RDEV. Importantly, Ebstracell addresses the top concerns from RDEV patients, itch, pain, inflammation, and wounds. Combined with the progress we've made in manufacturing and our discussions with regulators, we believe we're in a strong position as we move towards approval. Of course, the final decisions rest with the regulatory agencies. but our confidence in the program remains very high. Today I will review our strategy and capital priorities, including how we intend to advance EXPRO after we've had regulatory clarity on Ebstracell. Mark will then discuss Ebstracell's approval process and commercial readiness. Cory will review our financial results and I will return to summarize the milestones ahead before we take your questions. Before I discuss our regulatory timelines, I want to introduce Alex Hersham, whose child lives with R-Dub. Alex has kindly agreed to join us today to share his perspective as a father and what this disease means for his family. Alex recently visited our manufacturing center in Stevenage and met with the team working on Ebstracell. For all of us at Immune Bio, hearing directly from families gives our work a deep personal meaning. Behind every clinical endpoint and regulatory milestone is a child, a parent, and a family hoping for a better day's life. Every member of our team, whether in the laboratory, in manufacturing, and across the company has a role in advancing that goal and shares this mission wholeheartedly. That responsibility gives us urgency and purpose. Our job is to bring the same care and determination to develop potential treatments that families bring to caring for their children every day. Alex, thank you for being here and sharing your family's experience. I'll turn it over to you.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API